India | Agrochemicals Quarterly Update/Target price change

Chambal Fertilisers



Lower urea volume drags EBITDA

Revenue drop led by lower gas cost and lower traded volume

Chambal Fertilisers (CHMB IN) reported 49% EBITDA growth to INR 1.7bn but it was lower than our estimates of INR 3.8bn. Lower-than-expected EBITDA growth was due to a 13% YoY decline in urea sales volume, lower profitability in the ammonia business and maintenance shutdown-related cost. In FY25, we expect urea business to turnaround, driven by better volume and cost savings aided by energy efficiency initiatives. We also expect traded fertilizer and crop protection businesses to deliver better profit in FY25.

Energy efficiency and better volume to drive urea business in FY25

Urea volume declined 13% to 0.7mn tonne, due to weak demand amid rising channel inventory. Shutdown cost was incurred for two plants and marred profitability. We expect 4.4% urea volume growth to 3.4mn tonne in FY25E, driven by expectations of onset of the *La Nina* phenomenon along with the Monsoon, which should result in good rainfall. CHMB has improved urea energy consumption in two of its fertilizers plants, which should cut cost of production, thereby lifting EBITDA per tonne for the urea business. Further investment in energy efficiency initiatives are planned over 2-3 years.

Valuation: retain Reduce with a higher TP of INR 397

CHMB is evaluating its entry in the nitric acid value chain post completion of the technical ammonium nitrate (TAN) project, which would ease concerns on capital allocation. Fertilizer, which is a large part of the current business, stands on a solid footing but lacks a growth driver. On top of that, there is an overhang of quantum of EBITDA erosion post expiry of benefits for its G3 plant at Gadepan in Rajasthan in CY27. While management is making efforts to grow the business, we do not have clarity on growth visibility beyond the TAN project, which can offset potential EBITDA erosion post expiry of benefits. Hence, we reiterate **Reduce** with a higher TP of INR 397 from INR 345 based on 10x (unchanged) FY26E EPS of INR 39.7 despite an efficient business model and good management pedigree. We raise our EBITDA by 7% and PAT by 10% for FY25E and introduce FY26 estimates.

Rating: Reduce

Target Price: INR 397

Downside: 2%

CMP: INR 405 (as on 8 May 2024)

Kev	data
VGA	uata

Bloomberg/Reuters Code	CHMB IN/CHMB.BO
Current /Dil Shares O/S (mn)	401/401
Mkt Cap (INR bn/USD mn)	162/1,941
Daily Volume (3M NSE Avg)	2,514,519
Face Value (INR)	10

1 USD = INR 83.5

Note: *as on 8 May 2024; Source: Bloomberg

Price & Volume



Source: Bloomberg

Shareholding (%)	Q1FY24	Q2FY24	Q3FY24	Q4FY24
Promoter	60.6	60.6	60.6	60.7
Institutional Investor	21.6	19.9	22.7	22.1
Other Investor	4.1	4.4	4.3	4.2
General Public	13.8	15.2	12.4	13.0

Source: BSE

Price performance (%)	3M	6M	12M
Nifty	2.7	14.7	22.1
Chambal Fertilisers	11.6	34.8	34.6
Coromandel International	12.7	9.2	23.8
Rallis India	6.2	24.8	44.3

Source: Bloomberg

Financials (INR mn)	Q4FY24	Q4FY23	YoY (%)	Q3FY24	QoQ (%)	FY24	FY23	YoY (%)
Cons Net Sales	26,430	35,987	(26.6)	43,486	(39.2)	179,664	277,728	(35.3)
Raw Materials	14,116	22,087	(36.1)	24,375	(42.1)	109,023	197,043	(44.7)
% of Net Sales	53	61	(797)bp	56	(264)bp	61	71	(1,027)bp
Employee Cost	572	489	17.0	563	1.6	2,208	1,910	15.6
Other Expenses	10,077	12,296	(18.0)	12,263	(17.8)	48,001	60,582	(20.8)
Total Expenditure	24,765	34,872	(29.0)	37,201	(33.4)	159,232	259,535	(38.6)
EBITDA	1,665	1,114	49.4	6,285	(73.5)	20,433	18,194	12.3
Margin (%)	6	3	320bp	14	(815)bp	11	7	482bp
Depreciation	781	759	2.8	791	(1.3)	3,128	3,083	1.5
EBIT	884	355	148.9	5,494	(83.9)	17,305	15,111	14.5
Interest	360	669	(46.2)	365	(1.3)	1,731	3,200	(45.9)
Other Income	629	413	52.4	955	(34.1)	2,491	1,678	48.5
PBT	1,154	99	1,060.7	6,084	(81.0)	18,066	13,588	33.0
Tax	291	(876)	(133.2)	2,048	(85.8)	6,112	3,825	59.8
Tax Rate (%)	25	(881)	90,638bp	34	(847)bp	34	28	568bp
RPAT	863	975	(11.5)	4,036	(78.6)	11,954	9,763	22.4
Share of profit from JV	105	(36)	(395.2)	558	(81.2)	804	575	39.8
APAT	968	940	3.0	4,594	(78.9)	12,758	10,338	23.4
Adj EPS	2	2	7.0	11	(78.1)	31	25	23.8

YE	Revenue	YoY	EBITDA	EBITDA	Adj PAT	YoY	RoE	RoCE	P/E	EV/EBITDA
March	(INR mn)	(%)	(INR mn)	margin (%)	(INR mn)	(%)	(%)	(%)	(x)	(x)
FY23	277,728	72.8	18,194	6.6	10,338	(34.0)	14.6	10.6	10.6	6.8
FY24	179,664	(35.3)	20,433	11.4	12,758	23.4	17.5	12.8	11.2	6.9
FY25E	167,757	(6.6)	23,814	14.2	15,805	23.9	19.7	13.7	10.7	7.1
FY26E	168,197	0.3	24,851	14.8	16,506	4.4	17.2	13.4	10.7	6.3




Consolidated Financials (YE March)

Income Statement (INR mn)	FY23	FY24	FY25E	FY25
Net Revenues	277,728	179,664	167,757	168,19
EBITDA	18,194	20,433	23,814	24,85
Less :- Depreciation & Amortization	3,083	3,128	3,189	3,43
EBIT	15,111	17,305	20,625	21,41
Less:- Interest Expenses	3,200	1,731	1,000	1,00
Add:- Non operating Income	1,678	2,491	2,802	3,02
PBT	13,588	18,065	22,428	23,44
Less :- Taxes	3,825	6,112	7,438	7,76
Add: Share of profit in Associate/JV	575	804	815	83
Adjusted PAT	10,338	12,758	15,805	16,50
Reported PAT	10,338	12,758	15,805	16,50
Balance Sheet (INR mn)	FY23	FY24	FY25E	FY25
Share Capital	4,162	4,006	4,006	4,00
Reserves	66,519	68,731	76,293	91,82
Minority Interest	(152)	(155)	(130)	(130
Borrowings	33,353	18,536	22,145	12,95
Deferred Tax (Net)	7,043	10,258	10,258	10,25
Trade Payable	12,115	7,938	7,634	7,57
Other Liabilities	4,660	5,778	4,044	4,05
Total Liabilities	127,701	115,092	124,249	130,54
Gross Block	79,003	83,764	87,364	101,19
Less:- Accumulated Depreciation	16,595	19,723	22,912	26,34
Net Block	62,408	64,040	64,452	74,85
CWIP	1,026	1,839	8,839	50
Other Non-Current Assets	7,879	8,319	7,206	7,26
Cash & bank balances	576	1,331	1,352	5,14
Inventory	13,738	12,547	8,273	8,29
Trade Receivable	17,605	1,916	10,275	10,62
Other Net Assets	24,468	25,100	23,852	23,86
Total Assets	127,701	115,092	124,249	130,54
Cash Flow Statement (INR mn)	FY23	FY24	FY25E	FY25
Cash profit adjusted for non-cash items	20,285	22,939	23,814	24,85
Add/Less: Working Capital Changes	14,823	13,774	(11,673)	(46)
Taxes Paid	(2,715)	(3,446)	(3,905)	(4,078
Operating Cash Flow	32,393	33,267	8,236	20,31
Less:- Capex	(1,977)	(6,121)	(10,600)	(5,50
Free Cash Flow	30,415	27,146	(2,364)	14,81
Financing Cash Flow	(18,620)	(28,714)	(514)	(14,150
Investing Cash Flow	(18,732)	(3,823)	(7,700)	(2,374
Net change in Cash	(4,959)	730	22	3,78
Ratio Analysis	FY23	FY24	FY25E	FY25
Income Statement Ratios (%)				
Revenue Growth	26.3	72.8	(35.3)	(6.
EBITDA Growth	(19.6)	12.3	16.5	4.
PAT Growth	(34.0)	23.4	23.9	4.
EBITDA Margin	6.6	11.4	14.2	14.
Net Margin	3.7	7.1	9.4	9.
Return & Liquidity Ratios (%)				
Net Debt/Equity (x)	0.2	(0.0)	0.0	(0.
ROE (%)	14.6	17.5	19.7	17.
ROCE (%)	10.6	12.8	13.7	13.
Per Share data & Valuation Ratios				
Diluted EPS (INR)	24.8	30.7	38.0	39.
EPS Growth (%)	(34.0)	23.4	23.9	4.
	7.5	7.5	7.5	9
DPS (INR)		11.2	10.7	10.
• •	10.6	1 I.Z		
P/E (x)	10.6 6.8	6.9	7.1	6.
P/E (x) EV/EBITDA (x)				
DPS (INR) P/E (x) EV/EBITDA (x) EV/Sales (x) BVPS (INR)	6.8	6.9	7.1	6. 0. 239.


Note: Pricing as on 8 May 2024; Source: Company, Elara Securities Estimate

Revenue & margin trend




Source: Company, Elara Securities Estimate

Adjusted profit growth trend



Source: Company, Elara Securities Estimate

Return ratios



Source: Company, Elara Securities Estimate



Traded business volume to depend on subsidy regime

Traded business volume declined 46% YoY to 0.9mn tonne in FY24, due to non-remunerative subsidy policies. Management intends to engage in only profitable trading business. Given the current subsidy regime is not remunerative for diammonium phosphate (DAP), we expect DAP volume to be lower. Complex fertilizer and potash volume may be in line with the past year's overall; we expect stable volume but better profitability.

Multi-pronged efforts to drive crop protection biz

CHMB is making efforts to drive crop protection and specialty nutrient businesses. These range from 1) marketing arrangements with multinational innovator companies for access to new-age molecules, 2) collaborating with R&D institutions for biological products, 3) sourcing arrangements with cost-efficient and backward integrated manufacturers for off patent

molecules, 4) expanding to newer geographies & increasing depth in existing geographies, and 5) deepening engagement with farmers by leveraging digital & physical infrastructure and seeds for the harvest program.

TAN project going on as per schedule

The TAN project implementation is progressing as per plan, statutory approvals have been received and construction activity is in full swing. CHMB has invested INR 2.6bn in FY24 and plans to invest INR 7.0bn in FY25. Total project cost is INR 16.5bn for a 0.24-mn-tonne capacity plant. TAN is a commodity business, in our view with low TAN-Ammonia spread currently. Hence, we have built in minor financial benefits from TAN in FY26.

Exhibit 1: Urea volume down 13% in Q4FY24

	Q4FY24	Q4FY23	YoY (%)	Q3FY24	QoQ (%)	FY24	FY23	YoY (%)
Urea								
Volume (tonne)	666,000	764,000	(12.8)	892,000	(25.3)	3,255,000	3,440,000	(5.4)
Revenue (INR mn)	25,320	31,190	(18.8)	36,340	(30.3)	127,220	166,890	(23.8)
Realization (INR)	38,018	40,825	(6.9)	40,740	(6.7)	39,084	48,515	(19.4)
Trading business volume down significantly								
Volume (tonne)	20,000	506,000	(96.0)	118,000	(83.1)	867,000	1,927,000	(55.0)
DAP + NPK (tonne)	1,000	451,000	(99.8)	82,000	(98.8)	713,000	1,738,000	(59.0)
MOP (tonne)	19,000	55,000	(65.5)	36,000	(47.2)	154,000	189,000	(18.5)
Revenue (INR mn)	960	4,640	(79.3)	5,110	(81.2)	44,840	103,670	(56.7)
Blended realization (INR)	48,000	9,170	423.4	43,305	10.8	51,719	53,799	(3.9)
Subsidy outstanding down drastically								
Subsidy outstanding (INR mn)	1,340	16,400	(91.8)	4,680	(71.4)	1,340	16,400	(91.8)
Subsidy receipt (INR mn)	24,520	55,230	(55.6)	22,570	8.6	144,800	212,190	(31.8)
Net debt (INR mn)	(2,600)	13,910	(118.7)	(14,470)	(82.0)	(2,600)	13,910	(118.7)

Source: Company, Elara Securities Research

Exhibit 2: Healthy expansion in the urea and traded fertilizer businesses

Segment financials	Q4FY24	Q4FY23	YoY (%)	Q3FY24	QoQ (%)
Urea and traded fertilizer					
Revenue (INR mn)	26,278	35,831	(26.7)	41,453	(36.6)
Volume (tonne)	686,000	1,270,000	(46.0)	1,010,000	(32.1)
EBIT (INR mn)	933	285	227.6	5,497	(83.0)
Margin (%)	3.6	0.8	276bp	13.3	(971)bp
EBIT/tonne	1,360	224	506.5	5,443	(75.0)
Crop protection and specialty nutrients (CPC & SN)					
Revenue (INR mn)	152	156	(2.3)	2,033	(92.5)
EBIT (INR mn)	10	(9.2)	(207.6)	435	(97.7)
Margin (%)	6.5	(5.9)	(210.2)	21	(69.5)

Source: Company, Elara Securities Research

Exhibit 3: Change in estimates

(INR mn)	Old	New	Change (%)	New
	FY25E	FY25E	FY25E	FY26E
Net sales	173,158	167,757	(3.1)	168,197
EBITDA	22,322	23,814	6.7	24,851
EBITDA margin (%)	12.9	14.2	130	14.8
Adjusted PAT	14,342	15,805	10.2	16,506
EPS (INR)	34.5	38.0	10.1	39.7
TP (INR)	345	397	14.9	

Source: Elara Securities Estimate



Coverage History



AC=Analyst change

	Date	Rating	Target Price	Closing Price
7	31-Jan-2022	Reduce	INR 432	INR 432
8	20-May-2022	Accumulate	INR 432	INR 396
9	4-Aug-2022	Buy	INR 432	INR 320
10	23-Sep-2022	Buy	INR 459	INR 330
11	2-Nov-2022	Buy	INR 385	INR 308
12	29-May-2023	Accumulate	INR 314	INR 286
13	6-Feb-2024	Reduce	INR 345	INR 358
14	8-May-2024	Reduce	INR 397	INR 405

Guide to Research Rating

olute Return +5% to +20%
olute Return -5% to +5%
olute Return < -5%



Elara Securities (India) Private Limited

Disclosures & Confidentiality for non U.S. Investors

The Note is based on our estimates and is being provided to you (herein referred to as the "Recipient") only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient in understanding / evaluating the Proposal. Nothing in this document should be construed as an advice to buy or sell or solicitation to buy or sell the securities of companies referred to in this document. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. Nevertheless, Elara Securities (India) Private Limited or any of its affiliates is committed to provide independent and transparent recommendation to its client and would be happy to provide any information in response to specific client queries. Elara Securities (India) Private Limited or any of its affiliates have not independently verified all the information given in this Note and expressly disclaim all liability for any errors and/or omissions, representations or warranties, expressed or implied as contained in this Note. The user assumes the entire risk of any use made of this information, Elara Securities (India) Private Limited or any of its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for or solicit investment banking or other business from any company referred to in this Note. Each of these entities functions as a separate, distinct and independent of each other. This Note is strictly confidential and is being furnished to you solely for your information. This Note should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This Note is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Elara Securities (India) Private Limited or any of its affiliates to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe, any such restrictions. Upon request, the Recipient will promptly return all material received from the company and/or the Advisors without retaining any copies thereof. The Information given in this document is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This Information is subject to change without any prior notice. Elara Securities (India) Private Limited or any of its affiliates reserves the right to make modifications and alterations to this statement as may be required from time to time. However, Elara Securities (India) Private Limited is under no obligation to update or keep the information current. Neither Elara Securities (India) Private Limited nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. This Note should not be deemed an indication of the state of affairs of the company nor shall it constitute an indication that there has been no change in the business or state of affairs of the company since the date of publication of this Note. The disclosures of interest statements incorporated in this document are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. Elara Securities (India) Private Limited generally prohibits its analysts, persons reporting to analysts and their family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited. It is important to note that any dispute with respect to this research report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Elara Securities (India) Private Limited was incorporated in July 2007 as a subsidiary of Elara Capital (India) Private Limited.

Elara Securities (India) Private Limited is a SEBI registered Stock Broker in the Capital Market and Futures & Options Segments of National Stock Exchange of India Limited [NSE], in the Capital Market Segment of BSE Limited [BSE] and a Depository Participant registered with Central Depository Services (India) Limited [CDSL].

Elara Securities (India) Private Limited's business, amongst other things, is to undertake all associated activities relating to its broking business

The activities of Elara Securities (India) Private Limited were neither suspended nor has it defaulted with any stock exchange authority with whom it is registered in last five years. However, during the routine course of inspection and based on observations, the exchanges have issued advise letters or levied minor penalties on Elara Securities (India) Private Limited for minor operational deviations in certain cases. Elara Securities (India) Private Limited has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has the certificate of registration been cancelled by SEBI at any point of time.

Elara Securities (India) Private Limited offers research services primarily to institutional investors and their employees, directors, fund managers, advisors who are registered or proposed to be registered.

Details of Associates of Elara Securities (India) Private Limited are available on group company website www.elaracapital.com

Elara Securities (India) Private Limited is maintaining arms-length relationship with its associate entities.

Research Analyst or his/her relative(s) may have financial interest in the subject company. Elara Securities (India) Private Limited does not have any financial interest in the subject company, whereas its associate entities may have financial interest. Research Analyst or his/her relative does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Research Analyst or his/her relative or Elara Securities (India) Private Limited or its associate entities does not have any other material conflict of interest at the time of publication of the Research Report.

Research Analyst or his/her relative(s) has not served as an officer, director or employee of the subject company.

Research analyst or Elara Securities (India) Private Limited have not received any compensation from the subject company in the past twelve months. Associate entities of Elara Securities (India) Private Limited may have received compensation from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities have not managed or co-managed public offering of securities for the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company or third party in connection with the Research Report in the past twelve months.

Disclaimer & Standard warning

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Elara Securities (India) Private Limited



Disclaimer for non U.S. Investors

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

Disclosures for U.S. Investors

The research analyst did not receive compensation from Chambal Fertilisers Limited.

Elara Capital Inc.'s affiliate did not manage an offering for Chambal Fertilisers Limited.

Elara Capital Inc.'s affiliate did not receive compensation from Chambal Fertilisers Limited in the last 12 months.

Elara Capital Inc.'s affiliate does not expect to receive compensation from Chambal Fertilisers Limited in the next 3 months.

Disclaimer for U.S. Investors

This material is based upon information that we consider to be reliable, but Elara Capital Inc. does not warrant its completeness, accuracy or adequacy and it should not be relied upon as such.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities, financial instruments or strategies mentioned herein may not be suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only correct as of the stated date of their issue. Prices, values or income from any securities or investments mentioned in this report may fall against the interests of the investor and the investor may get back less than the amount invested. Where an investment is described as being likely to yield income, please note that the amount of income that the investor will receive from such an investment may fluctuate. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. The information contained in this report does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation of particular securities, financial instruments or strategies to you. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.

Certain statements in this report, including any financial projections, may constitute "forward-looking statements." These "forward-looking statements" are not guarantees of future performance and are based on numerous current assumptions that are subject to significant uncertainties and contingencies. Actual future performance could differ materially from these "forward-looking statements" and financial information.



Elara Securities (India) Private Limited

India Elara Securities (India) Pvt. Ltd. One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel: +91 22 6164 8500			Elara Securities Inc. 230 Park Avenue, Suite 2415, New Cyork, Ny 10169, USA Tel: +1 212 430 5870 S	Asia / Pacific Elara Capital (Asia) Pte.Ltd. Dne Marina Boulevard, .evel 20, Singapore 018989 Fel : +65 6978 4047
Harendra Kumar	Managing D	Director	harendra.kumar@elaracapital.com	+91 22 6164 857
Sales Ashok Agarwal	India		ashok.agarwal@elaracapital.com	+91 22 6164 8558
Hitesh Danak	India		hitesh.danak@elaracapital.com	+91 22 6164 8543
Karan Rathod	India		karan.rathod@elaracapital.com	+91 22 6164 8570
Lekha Nahar	India		lekha.nahar@elaracapital.com	+91 22 6164 851
Prashin Lalvani	India		prashin.lalvani@elaracapital.com	+91 22 6164 854
Shraddha Shrikhande	India		shraddha.shrikhande@elaracapital.com	+91 22 6164 856
Sudhanshu Rajpal	India		sudhanshu.rajpal@elaracapital.com	+91 22 6164 850
Joshua Saldanha	Asia		joshua.saldanha@elaracapital.com	+91 22 6164 854
Anita Nazareth		ccess, Conference & Events	anita.nazareth@elaracapital.com	+91 22 6164 852
Tina D'souza	Corporate A		tina.dsouza@elaracapital.com	+91 22 6164 859
Quantitative, Alternatives,			cupil inip@olaracapital.com	+01 22 6164 952
Sunil Jain Nandish Patel		e & Alternates e & Alternates	sunil.jain@elaracapital.com nandish.patel@elaracapital.com	+91 22 6164 853 +91 22 6164 856
Biren Mehta	Head - Sales		biren.mehta@elaracapital.com	+91 22 6164 850
Kalpesh Parekh	India	···	kalpesh.parekh@ElaraCapital.com	+91 22 6164 855
Manoj Murarka	India		manoj.murarka@elaracapital.com	+91 22 6164 855
Anil Pawar	India		anil.pawar@elaracapital.com	+91 22 6164 855
Nilesh Chheda	India		nilesh.chheda@elaracapital.com	+91 22 6164 855
Nupur Barve	India		nupur.barve@elaracapital.com	+91 22 6164 853
Research				
Dr Bino Pathiparampil	Head of Researc	ch Healthcare, Pharmaceuticals, Strategy	bino.pathiparampil@elaracapital.con	n +91 22 6164 8689
Amit Purohit	Analyst	Building Materials, FMCG, Paints	amit.purohit@elaracapital.com	+91 22 6164 8594
Ankita Shah	Analyst	Infrastructure, Ports & Logistics, Industrials	ankita.shah@elaracapital.com	+91 22 6164 8516
Biju Samuel	Analyst	Quantitative & Alternate Strategy	biju.samuel@elaracapital.com	+91 22 6164 8505
Gagan Dixit	Analyst	Aviation, Chemicals, Oil & Gas	gagan.dixit@elaracapital.com	+91 22 6164 8504
Garima Kapoor	Economist	Capital Coods Consumo Electronico	garima.kapoor@elaracapital.com	+91 22 6164 8527
Harshit Kapadia	Analyst	Capital Goods, Consumer Electronics	harshit.kapadia@elaracapital.com	+91 22 6164 8542
Jay Kale, CFA Karan Taurani	Analyst Analyst	Auto & Auto Ancillaries Media & Entertainment, Alcobev, QSR, Internet	jay.kale@elaracapital.com karan.taurani@elaracapital.com	+91 22 6164 8507 +91 22 6164 8513
Prakhar Agarwal	Analyst	Banking & Financials	prakhar.aqarwal@elaracapital.com	+91 22 6164 8502
Prashant Biyani	Analyst	Agrochemicals, Fertilisers, Hotels, Sugar	prakhant.biyani@elaracapital.com	+91 22 6164 8581
Prerna Jhunjhunwala	Analyst	Textiles, Retail	prerna.jhunjhunwala@elaracapital.co	
Ravi Sodah	Analyst	Cement, Metals & Mining	ravi.sodah@elaracapital.com	+91 22 6164 8517
Rupesh Sankhe	Analyst	Utilities, Renewables, Capital Goods, Real Estate		+91 22 6164 8518
Shweta Daptardar	Analyst	Diversified Financials, Non Lending Financials	shweta.daptardar@elaracapital.com	+91 22 6164 8559
Saurabh Mitra	Sr. Associate	Cement, Metals & Mining	saurabh.mitra@elaracapital.com	+91 22 6164 8546
Aditya Jaiswal	Associate	Strategy	aditya.jaiswal@elaracapital.com	+91 22 4204 8683
Amogh Deshpande	Associate	Aviation, Chemicals, Oil & Gas	amogh.deshpande@elaracapital.con	
Bhavi Shah	Associate	Cement, Metals & Mining	bhavi.shah@elaracapital.com	+91 22 6164 8521
Devarshi Raj	Associate	Diversified Financials, Non Lending Financials	devarshi.raj@elaracapital.com	+91 22 6164 8500
Gnyan Thaker	Associate	Textiles, Retail	gnyan.thaker@elaracapital.com	+91 22 6164 8500
Jinesh Kothari Kartik Solanki	Associate Associate	Infrastructure, Ports & Logistics Banking & Financials	jinesh.kothari@elaracapital.com	+91 22 6164 8500
Kashish Thakur	Associate	Healthcare, Pharmaceuticals	kartik.solanki@elaracapital.com kashish.thakur@elaracapital.com	+91 22 4204 8604 +91 22 6164 8569
Kasnish makur Keval Shah	Associate	Strategy	keval.shah@elaracapital.com	+91 22 4204 8669
Mihir Vora	Associate	Auto & Auto Ancillaries	mihir.vora@elaracapital.com	+91 22 6164 8500
Mudit Kabra	Associate	Capital Goods, Consumer Electronics	mudit.kabra@elaracapital.com	+91 22 4204 8611
Nemish Sundar	Associate	Capital Goods, Consumer Electronics	nemish.sundar@elaracapital.com	+91 22 4204 8683
Nishant Chowhan, CFA	Associate	Auto & Auto Ancillaries	nishant.chowhan@elaracapital.com	+91 22 4204 8667
Palak Shah	Associate	Banking & Financials	palak.shah@elaracapital.com	+91 22 4204 8682
Ragini Pande	Associate	Utilities, Renewables	ragini.pande@elaracapital.com	+91 22 6164 8500
Rohit Harlikar	Associate	Building Materials, FMCG, Paints	rohit.harlikar@elaracapital.com	+91 22 6164 8562
Rounak Ray	Associate	Media & Entertainment, Alcobev, QSR, Internet		+91 22 4204 8684
Runit Kapoor	Associate	Healthcare, Pharmaceuticals	runit.kapoor@elaracapital.com	+91 22 6164 8500
Shweta Roy	Associate	Economics	shweta.roy@elaracapital.com	+91 22 6164 8500
Subhankar Sanyal Tanvi Tambat	Associate Associate	Economics Real Estate	subhankar.sanyal@elaracapital.com tanvi.tambat@elaracapital.com	+91 22 4204 8688 +91 22 6164 8537
Jiwal Wadighare	Associate	Agrochemicals, Fertilisers, Hotels, Sugar	ujwal.wadighare@elaracapital.com	+91 22 4204 8684
Vidhi Puj	Associate	Building Materials, FMCG, Paints	vidhi.puj@elaracapital.com	+91 22 4204 8692
Vinayak Patil	Database	Salaring Materials, FMCG, Fairio	vinayak.patil@elaracapital.com	+91 22 6164 8510
Priyanka Sheth	Editor		priyanka.sheth@elaracapital.com	+91 22 6164 8568
Prakriti Singh	Editor		prakriti.singh@elaracapital.com	+91 22 6164 8500
Gurunath Parab	Production		gurunath.parab@elaracapital.com	+91 22 6164 8515
Jinesh Bhansali	Production		jinesh.bhansali@elaracapital.com	+91 22 6164 8537

Access our reports on Bloomberg: Type RESP ESEC <GO>

Jinesh Bhansali

Production

Also available on Thomson & Reuters

jinesh.bhansali@elaracapital.com

Elara Securities (India) Private Limited

Registered Office Address: One International Center, Tower 3, 21st Floor, Senapati Bapat Marg,
Elphinstone Road (West) Mumbai – 400 013, India Tel: +91 22 6164 8500
CIN: U74992MH2007PTC172297 | SEBI Research Analyst Registration No.: INH000000933
Member of BSE Limited and National Stock Exchange of India Limited | SEBI REGN. NO.: INZ 000 238236
Member of Central Depository Services (India) Limited | SEBI REGN. NO.: IN-DP-370-2018
Investor Grievance Email ID: investor.grievances@elaracapital.com - Tel: +91 22 6164 8509 Compliance Officer: Mr. Anand Rao - Email ID: anand.rao@elaracapial.com - Tel. +91 22 6164 8509